Accepted for Publication: April 23, 2018.
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2018 Helman SR et al. JAMA Network Open.
Corresponding Author: Christian S. Hinrichs, MD, National Cancer Institute, 10 Center Dr, 4B04, Bethesda, MD 20892 (hinrichs@mail.nih.gov).
Author Contributions: Dr Hinrichs had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Helman, Stevanović, Campbell, Hinrichs.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Helman, Stevanović, Kwong, Hinrichs.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Kwong.
Administrative, technical, or material support: Stevanović, Doran.
Supervision: Stevanović, Hinrichs.
Conflict of Interest Disclosures: Dr Hinrichs’ laboratory receives research funding through a National Institutes of Health (NIH) Cooperative Research and Development Agreement with Kite Pharma unrelated to the work presented in this article. Dr Hinrichs is an inventor on NIH patents in the field of cellular therapy for cancer. Dr Stevanović is an inventor on NIH patents unrelated to the work presented in this article. No other disclosures were reported.
Funding/Support: This work was supported by the Center for Cancer Research intramural research program of the National Cancer Institute.
Role of the Funder/Sponsor: The National Cancer Institute had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the National Cancer Institute Surgery Branch tumor-infiltrating lymphocyte laboratory for generation of samples.
2.Moody
CA, Laimins
LA. Human papillomavirus oncoproteins: pathways to transformation.
Nat Rev Cancer. 2010;10(8):550-560.
PubMedGoogle ScholarCrossref 3.Hinrichs
CS. Molecular pathways: breaking the epithelial cancer barrier for chimeric antigen receptor and T-cell receptor gene therapy.
Clin Cancer Res. 2016;22(7):1559-1564.
PubMedGoogle ScholarCrossref 11.International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents: volume 100 B: a review of human carcinogens.
IARC Monogr Eval Carcinog Risks Hum. 2012;100(pt B):1-441.
PubMedGoogle Scholar 12.Wheeler
CM, Hunt
WC, Joste
NE, Key
CR, Quint
WGV, Castle
PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.
J Natl Cancer Inst. 2009;101(7):475-487.
PubMedGoogle ScholarCrossref 13.Kreimer
AR, Clifford
GM, Boyle
P, Franceschi
S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.
Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-475.
PubMedGoogle ScholarCrossref 14.Kreimer
AR, Brennan
P, Lang Kuhs
KA,
et al. Human papillomavirus antibodies and future risk of anogenital cancer: a nested case-control study in the European Prospective Investigation Into Cancer and Nutrition Study.
J Clin Oncol. 2015;33(8):877-884.
PubMedGoogle ScholarCrossref 16.Stevanović
S, Draper
LM, Langhan
MM,
et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.
J Clin Oncol. 2015;33(14):1543-1550.
PubMedGoogle ScholarCrossref 17.Stevanović
S, Pasetto
A, Helman
SR,
et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.
Science. 2017;356(6334):200-205.
PubMedGoogle ScholarCrossref 18.Draper
LM, Kwong
MLM, Gros
A,
et al. Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6.
Clin Cancer Res. 2015;21(19):4431-4439.
PubMedGoogle ScholarCrossref 19.Trimble
CL, Morrow
MP, Kraynyak
KA,
et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Lancet. 2015;386(10008):2078-2088.
PubMedGoogle ScholarCrossref 20.Trimble
CL, Peng
S, Kos
F,
et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.
Clin Cancer Res. 2009;15(1):361-367.
PubMedGoogle ScholarCrossref 21.van den Hende
M, Redeker
A, Kwappenberg
KMC,
et al. Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-specific CD4+ memory T cell responses.
J Infect Dis. 2010;202(8):1200-1211.
PubMedGoogle ScholarCrossref 22.Nakagawa
M, Greenfield
W, Moerman-Herzog
A, Coleman
HN. Cross-reactivity, epitope spreading, and de novo immune stimulation are possible mechanisms of cross-protection of nonvaccine human papillomavirus (HPV) types in recipients of HPV therapeutic vaccines.
Clin Vaccine Immunol. 2015;22(7):679-687.
PubMedGoogle ScholarCrossref 23.Welters
MJP, van der Logt
P, van den Eeden
SJF,
et al. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease.
Int J Cancer. 2006;118(4):950-956.
PubMedGoogle ScholarCrossref 24.Maciag
PC, Radulovic
S, Rothman
J. The first clinical use of a live-attenuated
Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix.
Vaccine. 2009;27(30):3975-3983.
PubMedGoogle ScholarCrossref